Loading...
XNAS
DRMA
Market cap4mUSD
Jun 09, Last price  
0.76USD
1D
1.70%
1Q
-38.39%
IPO
-99.10%
Name

Dermata Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
24.06%
Rev. gr., 5y
%
Revenues
0k
Net income
-12.29b
L+157,538.87%
-4,972,104-3,433,799-7,948,090-9,610,913-7,794,690-12,287,461,000
CFO
-11.16b
L+174,078.00%
-3,922,272-4,028,541-5,693,392-8,834,164-6,408,931-11,162,948,000

Profile

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
IPO date
Aug 13, 2021
Employees
8
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
12,513,242
8,042
9,674
Unusual Expense (Income)
NOPBT
(12,513,242)
(8,042)
(9,674)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(12,513,242)
(8,042)
(9,674)
Net income
(12,287,461)
157,538.87%
(7,795)
-18.90%
(9,611)
20.92%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,885
7,606
4,277
BB yield
-333.40%
-6,395.25%
-94.62%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
1,164,783
497
Net debt
(3,161,570)
(7,438)
(6,241)
Cash flow
Cash from operating activities
(11,162,948)
(6,409)
(8,834)
CAPEX
Cash from investing activities
Cash from financing activities
6,886
7,606
4,277
FCF
(12,513,242)
(8,042)
(9,674)
Balance
Cash
3,161,570
7,438
6,241
Long term investments
Excess cash
3,161,570
7,438
6,241
Stockholders' equity
(65,675,339)
(53,387)
(45,592)
Invested Capital
69,207,254
59,743
51,614
ROIC
ROCE
EV
Common stock shares outstanding
1,530
195
691
Price
1.35
121.31%
0.61
-90.68%
6.54
-76.49%
Market cap
2,065
1,636.54%
119
-97.37%
4,520
-68.81%
EV
(3,159,505)
(7,319)
(1,722)
EBITDA
(12,513,242)
(8,042)
(9,674)
EV/EBITDA
0.25
0.91
0.18
Interest
64
Interest/NOPBT